JP2010502713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502713A5 JP2010502713A5 JP2009527422A JP2009527422A JP2010502713A5 JP 2010502713 A5 JP2010502713 A5 JP 2010502713A5 JP 2009527422 A JP2009527422 A JP 2009527422A JP 2009527422 A JP2009527422 A JP 2009527422A JP 2010502713 A5 JP2010502713 A5 JP 2010502713A5
- Authority
- JP
- Japan
- Prior art keywords
- particle
- particles
- item
- surface modifying
- units
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002245 particle Substances 0.000 claims description 146
- 239000000203 mixture Substances 0.000 claims description 38
- 210000003097 mucus Anatomy 0.000 claims description 30
- 239000012867 bioactive agent Substances 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002872 contrast media Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 125000006353 oxyethylene group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 238000012986 modification Methods 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000004793 Polystyrene Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84328206P | 2006-09-08 | 2006-09-08 | |
| PCT/US2007/019522 WO2008030557A2 (en) | 2006-09-08 | 2007-09-07 | Compositions and methods for enhancing transport through mucus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013110583A Division JP2013163697A (ja) | 2006-09-08 | 2013-05-27 | 粘液を通る輸送を増強するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502713A JP2010502713A (ja) | 2010-01-28 |
| JP2010502713A5 true JP2010502713A5 (cg-RX-API-DMAC7.html) | 2011-10-27 |
Family
ID=38945776
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527422A Withdrawn JP2010502713A (ja) | 2006-09-08 | 2007-09-07 | 粘液を通る輸送を増強するための組成物および方法 |
| JP2013110583A Withdrawn JP2013163697A (ja) | 2006-09-08 | 2013-05-27 | 粘液を通る輸送を増強するための組成物および方法 |
| JP2014256264A Active JP6297481B2 (ja) | 2006-09-08 | 2014-12-18 | 粘液を通る輸送を増強するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013110583A Withdrawn JP2013163697A (ja) | 2006-09-08 | 2013-05-27 | 粘液を通る輸送を増強するための組成物および方法 |
| JP2014256264A Active JP6297481B2 (ja) | 2006-09-08 | 2014-12-18 | 粘液を通る輸送を増強するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US20100215580A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2061433B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2010502713A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE498393T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007292902B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2663003C (cg-RX-API-DMAC7.html) |
| DE (1) | DE602007012559D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2360538T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008030557A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| CN101951895B (zh) * | 2008-02-18 | 2013-11-06 | Csir公司 | 药物给药用的纳米粒子载体及其制备方法 |
| CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| PT2563450T (pt) | 2010-04-28 | 2017-08-28 | Kimberly Clark Co | Dispositivo para entrega de medicação para a artrite reumatóide |
| EP2563452B1 (en) | 2010-04-28 | 2019-04-17 | Sorrento Therapeutics, Inc. | Composite microneedle array including nanostructures thereon |
| US9522262B2 (en) | 2010-04-28 | 2016-12-20 | Kimberly-Clark Worldwide, Inc. | Medical devices for delivery of siRNA |
| WO2012046149A1 (en) | 2010-04-28 | 2012-04-12 | Kimberly-Clark Worldwide, Inc. | Method for increasing permeability of an epithelial barrier |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| US10307372B2 (en) * | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| AU2011323250B2 (en) * | 2010-11-05 | 2015-11-19 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| AU2012328038B2 (en) | 2011-10-27 | 2016-11-17 | Kimberly-Clark Worldwide, Inc. | Implantable devices for delivery of bioactive agents |
| AU2012328037B2 (en) | 2011-10-27 | 2017-11-02 | Vivasor, Inc. | Transdermal delivery of high viscosity bioactive agents |
| US20170246439A9 (en) | 2011-10-27 | 2017-08-31 | Kimberly-Clark Worldwide, Inc. | Increased Bioavailability of Transdermally Delivered Agents |
| WO2013090804A2 (en) * | 2011-12-14 | 2013-06-20 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| CA2863632C (en) * | 2012-01-19 | 2017-07-11 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| EP2825206A1 (en) | 2012-03-16 | 2015-01-21 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
| US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9895437B2 (en) * | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
| US9827191B2 (en) * | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10864219B2 (en) * | 2012-05-03 | 2020-12-15 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| EP3808339B1 (en) * | 2012-05-03 | 2025-11-12 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| HK1208162A1 (en) * | 2012-05-03 | 2016-02-26 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
| US9889208B2 (en) | 2012-05-04 | 2018-02-13 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| EP3434774A1 (en) | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| PL3019619T3 (pl) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2015127389A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic enema formulations and methods of use |
| WO2015175545A1 (en) | 2014-05-12 | 2015-11-19 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| US10253045B2 (en) | 2014-11-26 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
| US10174022B2 (en) | 2014-12-10 | 2019-01-08 | Kala Pharmaceuticals, Inc. | 1-amino-triazolo(1,5-A)pyridine-substituted urea derivative and uses thereof |
| WO2016094880A1 (en) * | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
| RU2729731C2 (ru) | 2014-12-15 | 2020-08-11 | Зе Джонс Хопкинс Юниверсити | Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний |
| KR20240126072A (ko) | 2015-01-27 | 2024-08-20 | 더 존스 홉킨스 유니버시티 | 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제 |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| CN108366984A (zh) | 2015-09-22 | 2018-08-03 | 灰色视觉公司 | 用于治疗眼部病症的化合物和组合物 |
| JP7687767B2 (ja) | 2015-10-22 | 2025-06-03 | モデルナティエックス インコーポレイテッド | 呼吸器合胞体ウイルスワクチン |
| AU2016342049B2 (en) | 2015-10-22 | 2023-05-18 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP4349405A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
| CN118846026A (zh) | 2015-10-22 | 2024-10-29 | 摩登纳特斯有限公司 | 广谱流感病毒疫苗 |
| TN2018000152A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| CA3003733C (en) * | 2015-10-30 | 2021-04-20 | The Johns Hopkins University | Mucus penetrating particles with high molecular weight and dense coatings |
| EP3373978A4 (en) | 2015-11-12 | 2019-06-26 | Graybug Vision, Inc. | AGGREGATION OF MICROPARTICLES FOR THERAPY |
| LT3394093T (lt) | 2015-12-23 | 2022-04-25 | Modernatx, Inc. | Ox40 ligandus koduojančių polinukleotidų naudojimo būdai |
| WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| KR101741977B1 (ko) * | 2016-04-26 | 2017-05-31 | 한국교통대학교산학협력단 | 경구 투여용 유전자 전달을 위한 나노입자 및 이를 포함하는 약학 조성물 |
| KR20190036520A (ko) | 2016-06-27 | 2019-04-04 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물 |
| US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3037176A1 (en) * | 2016-09-16 | 2018-03-22 | Kala Pharmaceuticals, Inc. | Particles, compositions, and methods for ophthalmic and/or other applications |
| MX2019010381A (es) | 2017-03-01 | 2020-01-21 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos. |
| CA3056923A1 (en) | 2017-03-23 | 2018-09-27 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
| WO2018209155A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| US20210186880A1 (en) * | 2018-08-03 | 2021-06-24 | Brown University | Oral formulations with increased uptake |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| CN113365617B (zh) | 2018-10-16 | 2025-12-23 | 乔治亚州立大学研究基金会股份有限公司 | 用于医学疾病治疗的一氧化碳前药 |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| US20250197403A1 (en) | 2020-02-20 | 2025-06-19 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| WO2022066774A1 (en) | 2020-09-23 | 2022-03-31 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2022108937A2 (en) * | 2020-11-17 | 2022-05-27 | Phosphorex, Inc. | Novel drug delivery composition and process for blood-brain barrier crossing |
| JP2025508467A (ja) | 2022-02-24 | 2025-03-26 | アイオー バイオテック エーピーエス | 癌治療のヌクレオチド送達 |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4906474A (en) * | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4757128A (en) * | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| CH671402A5 (cg-RX-API-DMAC7.html) * | 1985-10-02 | 1989-08-31 | Sandoz Ag | |
| GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
| US4789724A (en) * | 1986-10-17 | 1988-12-06 | Massachusetts Institute Of Technology | Preparation of anhydride copolymers |
| US4839343A (en) * | 1987-03-13 | 1989-06-13 | Debiopharm, S.A. | Preparation containing hexatriacontapeptides and methods of use |
| US5718921A (en) * | 1987-03-13 | 1998-02-17 | Massachusetts Institute Of Technology | Microspheres comprising polymer and drug dispersed there within |
| US4868274A (en) * | 1988-05-23 | 1989-09-19 | Hoechst Celanese Corp. | Polyanhydride from carboxy aryloxy alkanoic acid |
| US4999417A (en) * | 1989-03-30 | 1991-03-12 | Nova Pharmaceutical Corporation | Biodegradable polymer compositions |
| US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5696298A (en) * | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| US6197346B1 (en) * | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6517860B1 (en) * | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
| GB9713980D0 (en) * | 1997-07-03 | 1997-09-10 | Danbiosyst Uk | New conjugates |
| US6355271B1 (en) * | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US20040258763A1 (en) * | 1999-02-03 | 2004-12-23 | Bell Steve J.D. | Methods of manufacture and use of calcium phosphate particles containing allergens |
| US20020068090A1 (en) * | 1999-02-03 | 2002-06-06 | Bell Steve J. D. | Calcium phosphate particles as mucosal adjuvants |
| US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| WO2001021154A2 (en) * | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
| US20040102197A1 (en) * | 1999-09-30 | 2004-05-27 | Dietz Timothy Alan | Dynamic web page construction based on determination of client device location |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| GB0027357D0 (en) * | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
| GB2370839A (en) * | 2001-01-06 | 2002-07-10 | Benedikt Timmerman | Immunogenic complex useful for disease control |
| ATE478656T1 (de) * | 2001-06-22 | 2010-09-15 | Univ Johns Hopkins Med | Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen |
| GB0200289D0 (en) * | 2002-01-08 | 2002-02-20 | Koninkl Philips Electronics Nv | Switched-current integrator |
| AU2006220411B2 (en) * | 2002-03-20 | 2008-06-26 | Alkermes, Inc. | Inhalable Sustained Therapeutic Formulations |
| WO2003103632A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| MXPA05003162A (es) * | 2002-09-26 | 2005-07-05 | Yamanouchi Pharma Co Ltd | Agentes mejoradores de absorbibilidad de droga. |
| BR0316685A (pt) * | 2002-12-17 | 2005-11-01 | Nastech Pharm Co | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade |
| US7060299B2 (en) * | 2002-12-31 | 2006-06-13 | Battelle Memorial Institute | Biodegradable microparticles that stabilize and control the release of proteins |
| WO2005014524A2 (en) * | 2003-08-07 | 2005-02-17 | Wisconsin Alumni Research Foundation | Amino thiol compounds and compositions for use in conjunction with cancer therapy |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| WO2005072710A2 (en) * | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| CA2555335A1 (en) * | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Rnai therapeutics for treatment of eye neovascularization diseases |
| ES2246694B1 (es) * | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| EP1768692B8 (en) * | 2004-07-01 | 2015-06-17 | Yale University | Targeted and high density drug loaded polymeric materials |
| EP1796650B1 (en) * | 2004-09-14 | 2009-01-07 | NanoDel Technologies GmbH | Delivery vehicle containing nanoparticles |
| WO2006044660A2 (en) * | 2004-10-14 | 2006-04-27 | Vanderbilt University | Functionalized solid lipid nanoparticles and methods of making and using same |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| WO2007067978A1 (en) * | 2005-12-09 | 2007-06-14 | Invitrogen Corporation | Optical in vivo imaging contrast agents and methods of use |
| ATE482690T1 (de) * | 2005-12-14 | 2010-10-15 | Hoffmann La Roche | Hcv-prodrug-formulierung |
| US20080102128A1 (en) * | 2006-07-28 | 2008-05-01 | Flamel Technologies, Inc. | Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them |
| US8821943B2 (en) * | 2006-09-12 | 2014-09-02 | Board Of Regents Of The University Of Nebraska | Methods and compositions for targeted delivery of therapeutic agents |
| US20090226531A1 (en) * | 2008-03-07 | 2009-09-10 | Allergan, Inc. | Methods and composition for intraocular delivery of therapeutic sirna |
| AU2011323250B2 (en) * | 2010-11-05 | 2015-11-19 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
-
2007
- 2007-09-07 US US12/310,751 patent/US20100215580A1/en not_active Abandoned
- 2007-09-07 DE DE602007012559T patent/DE602007012559D1/de active Active
- 2007-09-07 AT AT07837876T patent/ATE498393T1/de not_active IP Right Cessation
- 2007-09-07 ES ES07837876T patent/ES2360538T3/es active Active
- 2007-09-07 JP JP2009527422A patent/JP2010502713A/ja not_active Withdrawn
- 2007-09-07 EP EP07837876A patent/EP2061433B1/en not_active Revoked
- 2007-09-07 CA CA2663003A patent/CA2663003C/en active Active
- 2007-09-07 WO PCT/US2007/019522 patent/WO2008030557A2/en not_active Ceased
- 2007-09-07 AU AU2007292902A patent/AU2007292902B8/en active Active
-
2012
- 2012-12-03 US US13/692,442 patent/US20130164343A1/en not_active Abandoned
-
2013
- 2013-05-27 JP JP2013110583A patent/JP2013163697A/ja not_active Withdrawn
-
2014
- 2014-12-18 JP JP2014256264A patent/JP6297481B2/ja active Active
-
2016
- 2016-06-29 US US15/196,178 patent/US20170095566A1/en not_active Abandoned
-
2018
- 2018-05-17 US US15/982,447 patent/US20180264135A1/en not_active Abandoned
-
2020
- 2020-07-22 US US16/936,220 patent/US20200345864A1/en not_active Abandoned
-
2022
- 2022-08-05 US US17/882,132 patent/US20230108636A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502713A5 (cg-RX-API-DMAC7.html) | ||
| EP2804632B1 (en) | Nanoparticle formulations with enhanced mucosal penetration | |
| JP6590750B2 (ja) | 粘膜浸透が増強されたかまたは炎症が低減されたナノ粒子 | |
| Shaikh et al. | Mucoadhesive drug delivery systems | |
| Chae et al. | Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis | |
| Anitha et al. | Combinatorial nanomedicines for colon cancer therapy | |
| Wan et al. | Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects | |
| AU2018201772A1 (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| Binsalamah et al. | Nanomedicine in cardiovascular therapy: recent advancements | |
| WO2021254507A1 (zh) | 载药医疗器械及制备方法、药物球囊、药物涂层制备方法 | |
| Abo-zeid et al. | Polymer nanoparticle as a delivery system for ribavirin: Do nanoparticle avoid uptake by Red Blood Cells? | |
| El-Hammadi et al. | Nanotechnology for vaginal drug delivery and targeting | |
| JP2020532958A5 (cg-RX-API-DMAC7.html) | ||
| JP2018534244A5 (cg-RX-API-DMAC7.html) | ||
| CN107106489A (zh) | 用于丙型肝炎的长效药物组合物 | |
| Ray et al. | Recent patents on nanoparticles and nanoformulations for cancer therapy | |
| Zeinali et al. | Nanomaterials as a Versatile Tool for COVID-19 Treatment | |
| Razei et al. | Application of nanoparticles drug delivery systems in the treatment of intracellular bacterial infections | |
| Hsieh et al. | Nanostructured lipid carriers containing a high percentage of a Pluronic copolymer increase the biodistribution of novel PDE4 inhibitors for the treatment of traumatic hemorrhage | |
| Lee et al. | On-demand reconstitutable hyaluronic acid-doped azathioprine microcrystals effectively ameliorate ulcerative colitis via selective accumulation in inflamed tissues | |
| Kanojiya et al. | The Know-how of Polymeric Nanocarrier Based Vaginal Drug Delivery System: Pitfalls, Challenges and Trends | |
| Usharani et al. | Biomimetic nanomaterials for pulmonary infections: A prospective view in drug delivery systems | |
| US20240100047A1 (en) | Composition and method for treating covid-19 | |
| Dey et al. | Applications of nanotechnology in the treatment of pulmonary diseases | |
| Nadaf et al. | Nanostrategies for Infectious Pulmonary Diseases: Current Progress and Future Prospects |